Statistics: Anne Wojcicki Invested $250k on Shark Tank

One deal is not much of a Shark Tank record. Anne Wojcicki came into Season 11, agreed to invest in Gallant, and that was it. She never added a second company. So everything connected with Anne’s time as a Shark comes back to this one business.

Gallant was at least an interesting company for her to find. Anne had co-founded 23andMe and already spent years around healthcare, genetics and biotechnology. Aaron Hirschhorn had brought her a pet business built around stem cells. Gallant was dealing with the kind of science Anne already knew quite a bit about from her years with 23andMe.

Lori Greiner went into the deal with her. Together, Anne and Lori agreed to give Gallant $500,000 for 5% of the company. Anne’s part comes to $250,000 if the money is divided equally between the two Sharks. That one half of one deal gives Anne her complete accepted Shark Tank amount.

Except the money apparently never got there. The Gallant deal reportedly did not close once Shark Tank was over, which makes Anne’s very short investment record even shorter when we look at money that can actually be supported as invested. She agreed to $250,000 in the Tank, but there isn’t enough public evidence to say Anne actually put that $250,000 into Gallant.

How Much Did Anne Wojcicki Invest on Shark Tank?

Aaron Hirschhorn was asking for $500,000 for only 2% of Gallant. That put the company at a $25 million valuation, and he was not very interested in giving much more of it away. Anne Wojcicki and Lori Greiner eventually offered the $500,000, but they wanted 8%. Aaron came back with 4%.

Anne and Lori did not take the 4%, but they did come down. They moved to 5%, Aaron accepted, and the $500,000 deal was made. So, he had started by offering 2% and ended up giving the two Sharks 5%. The valuation came down to around $10 million with it.

There were two Sharks putting up the $500,000. With nothing showing that Anne and Lori planned to split the cash differently, Anne’s side comes to $250,000 and Lori’s comes to another $250,000. The 5% equity can be divided the same way, leaving Anne with 2.5% based on the accepted deal.

And that $250,000 does not have another investment sitting beside it. Gallant was Anne’s only accepted deal, so her Season 11 amount is also her complete Shark Tank amount. She agreed to invest $250,000 during her time on the show. Whether that money actually went into Gallant is a different part of the story.

Anne Wojcicki’s Gallant Investment

Aaron Hirschhorn was not trying his first pet business with Gallant. Before this, he had built DogVacay, which later became part of Rover. He already knew people spent plenty of money taking care of their pets. Gallant just gave them something very different to spend it on.

Gallant wanted to collect stem cells from tissue that was normally removed when pets were spayed or neutered. Usually, there would not be much reason to keep that tissue after the procedure. Gallant could collect the cells and preserve them in case they were useful for treatment later. The owner was paying to keep an option around for the future.

And there was quite a bit more science here than Aaron had with DogVacay. That happened to be the part Anne Wojcicki already knew. She had spent years around genetics, healthcare and biotechnology with 23andMe, while Aaron already had years of experience with the pet customer. Their experience came from two pretty different places.

Lori Greiner was beside Anne on the investment too. Gallant had to get ordinary pet owners comfortable with paying for something they might not use until years later, and Lori had plenty of experience getting people to understand new products. Anne had the scientific background, Lori knew consumer products, and Aaron knew pets. The two Sharks agreed to invest $500,000 for 5% of Gallant, with Anne’s side coming to $250,000.

Did Anne Wojcicki’s Gallant Deal Close?

The $500,000 agreement did not make it past Shark Tank. Aaron Hirschhorn accepted the offer from Anne Wojcicki and Lori Greiner, but the Gallant deal reportedly fell apart afterward. So, Anne and Lori agreed to invest in the company on the show, but the investment was never completed.

After filming, Shark Tank deals still have to go through due diligence. The Sharks can take a closer look at the company’s finances, ownership and other business details before the investment actually goes through. Sometimes everything works out and sometimes it doesn’t. Gallant ended up being one of the deals that didn’t.

Why it happened is not really clear. There isn’t a confirmed public explanation telling us what Anne, Lori or Aaron found after filming that caused the agreement to end. So, we know the deal fell apart, but not enough to say what specifically killed it. Anything more would be guessing.

For Anne, that makes a pretty big difference because Gallant was all she had. Her half of the accepted agreement was $250,000, and there was no second investment that came close to being put beside it. She still gets $250,000 when counting the deal she agreed to on Shark Tank. When looking for publicly supported money that actually went into her Shark Tank companies, there isn’t any.

What Happened to Gallant After Shark Tank?

Gallant started with banking stem cells, but it did not stay only there. The company later began developing stem-cell therapies for animals. Some of that work has involved feline chronic gingivostomatitis and osteoarthritis. The treatments still had to go through the FDA process, so Gallant had not reached the point where these were fully approved commercial treatments.

Then in 2025, Gallant raised $18 million in Series B funding. That is quite a bit of money for a company that once came to Shark Tank asking for $500,000. And Anne and Lori’s $500,000 never even made it into the company. Gallant had gone on to find much more funding without them.

Gallant was also looking ahead to getting its therapies into veterinary clinics. In 2026, the company began working with MWI Animal Health on the cold-chain infrastructure needed to distribute them. There was still development and approval to get through first. But Gallant was working on more than storing the cells by this point.

Aaron Hirschhorn was not around for these later years of the company. He died in a boating accident in 2021. Gallant continued under new leadership after Aaron died. His work with the company did not continue, but the biotechnology he started did.

Anne Wojcicki Net Worth

$270 million is one number we have for Anne Wojcicki. Forbes estimated her net worth around that amount in 2023, although Anne had been worth much more before that. She even reached billionaire status when 23andMe was doing much better. The problem is that 2023 was not the end of what happened with the company.

Anne’s ownership in 23andMe had made up a big part of her wealth. When the company lost value, that meant the value of her shares was falling too. Then 23andMe filed for bankruptcy in 2025. So, quite a lot changed after Forbes came up with that $270 million estimate.

And there isn’t a newer public number that neatly tells us what Anne is worth now. She has other assets and private investments, but we cannot see enough of those to simply add everything together. There isn’t enough public information to put an exact number on Anne’s wealth today. The $270 million estimate is from 2023, and too much has changed since then to treat it as her current net worth.

Anne’s Shark Tank activity was small beside all of this anyway. She only agreed to $250,000 for Gallant, and even that deal did not close. Most of the big changes in Anne’s wealth came from what was happening with 23andMe. Her one Shark Tank deal was never going to move that number very much.

What Happened to 23andMe?

23andMe had been Anne Wojcicki’s company since 2006, but the version of it that went public did not last. The company entered the stock market through a SPAC merger in 2021 with a valuation in the billions. Only four years later, 23andMe filed for Chapter 11 bankruptcy protection in March 2025. Anne resigned as CEO during the bankruptcy.

There were several problems by then. 23andMe was losing money and having trouble getting enough recurring revenue from customers. Its share price had also fallen badly. Then the company had a major data-security incident involving customer information, which was particularly difficult for a business where people had handed over their genetic information.

Anne did come back into the picture pretty quickly. Her nonprofit, TTAM Research Institute, made an offer of around $305 million for major 23andMe assets and won the bankruptcy auction. The purchase was completed in July 2025.

The bankruptcy did not wipe out everything 23andMe had built. The Personal Genome Service continued, and the research work carried on under TTAM too. Anne had spent almost twenty years around this genetics work by then. Now she was involved with it again, only under TTAM instead. TTAM is a nonprofit, and the $305 million it paid for the assets should not be counted as another $305 million that Anne personally owned.

Conclusion

Anne Wojcicki never really got the chance to find out what kind of Shark she would be. Gallant was her first accepted deal and then there was no second one. Her part of that agreement was $250,000, with Lori Greiner putting up the other half. And even the first one did not make it through after filming.

That leaves Anne in a funny place when trying to answer how much she invested on Shark Tank. $250,000 is easy enough if we are counting what she agreed to invest in the Tank. If we want money that can actually be supported as going into the company, there is nothing to count. Gallant never received Anne’s part of the $500,000 deal.

Gallant had a lot more to get through after Shark Tank. Aaron Hirschhorn died in 2021, but the company continued without him and raised $18 million in 2025. Gallant was also moving further into veterinary regenerative medicine by then. The deal with Anne and Lori was long gone, but the company was not.

23andMe was a much bigger part of Anne’s life than Shark Tank ever became. She had taken the company from its early years to a multibillion-dollar public business, only to see it go into bankruptcy in 2025. Anne later found her way back to the company’s genetics and research work. Through TTAM Research Institute, she took control of some of 23andMe’s major assets.